BioPorto A/S

Equities

BIOPOR

DK0011048619

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-07-16 EDT			5-day change	1st Jan Change
2.23 ^DKK	+0.45%		+7.21%	+6.70%

06-18	BioPorto to Raise DKK81 Million to Fund Clinical Trials	MT
05-30	BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024	CI

BioPorto A/S Proposes Appointment of Britt Meelby Jensen as Board Member

January 16, 2018 at 06:22 am

BioPorto A/S announced that its Board of Directors will nominate Britt Meelby Jensen for election as a new Board member at BioPorto's Annual General Meeting on April 13, 2018. Britt Meelby Jensen has extensive global commercial and general management experiences from working in the life sciences area over the past 16 years at Novo Nordisk, Dako and Zealand Pharma. Since 2015 Britt has been the CEO of Zealand Pharma A/S.

Latest news about BioPorto A/S

BioPorto to Raise DKK81 Million to Fund Clinical Trials	06-18	MT
BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024	05-30	CI
BioPorto A/S Appoints Niels Høy Nielsen as Chief Financial Officer, Effective August 1, 2024	05-30	CI
BioPorto A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Bioporto A/S Provides Earnings Guidance for 2024	05-08	CI
BioPorto Names New Chief Legal Officer	04-10	MT
Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024	04-10	CI
Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election	04-05	CI
BioPorto A/S Reports Earnings Results for the Full Year Ended December 31, 2023	04-04	CI
BioPorto Makes Interim CEO Permanent	04-02	MT
BioPorto A/S Appoints Peter Mørch Eriksen as Permanent Group CEO	04-02	CI
Bioporto A/S Announces Peter Mørch Eriksen Will Not Stand for Re-Election to the Board of Directors	04-02	CI
Transcript : BioPorto A/S - Special Call	02-22
BioPorto A/S Provides Revenue Guidance for the Full Year 2024	02-22	CI
Roche: extended collaboration with Denmark's BioPorto	02-20	CF
BioPorto Expands Global Distribution Partnership with Roche Diagnostics	02-20	MT
Roche Diagnostics and BioPorto A/S Expand Collaboration	02-20	CI
BioPorto CEO Steps Down; Interim Successor Appointed	01-10	MT
BioPorto A/S Announces CEO Changes	01-09	CI
Transcript : BioPorto A/S - Special Call	12-10
BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States	12-07	CI
BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member	12-04	CI
Transcript : BioPorto A/S, Q3 2023 Earnings Call, Nov 01, 2023	11-01
Transcript : BioPorto A/S, Q3 2023 Earnings Call, Nov 01, 2023	11-01
BioPorto A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI

Chart BioPorto A/S

Duration

Period

More charts

Company Profile

Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Companyâs portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-14 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.23 DKK

Average target price

5 DKK

Spread / Average Target

+124.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOPORTO A/S	+6.70%	140M
BIOMÉRIEUX	-6.66%	12.28B
LANTHEUS HOLDINGS, INC.	+90.81%	8.54B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-22.14%	6.58B
DIASORIN S.P.A.	+8.86%	5.77B
AUTOBIO DIAGNOSTICS CO., LTD.	-23.82%	3.48B
ANDON HEALTH CO., LTD.	+5.12%	2.54B
MYRIAD GENETICS, INC.	+43.10%	2.41B
VITROLIFE AB	-7.24%	2.3B
10X GENOMICS, INC.	-64.26%	2.07B

Diagnostic & Testing Substances